West Pharmaceutical Services stock gains after target rises

West Pharmaceutical Services stock stood at USD 375.97 on the NYSE on September 23, 2026, up 1.32 percent from the prior session and 2.6 percent below its 52-week high of USD 386. The latest analyst move adds a valuation signal to the market picture.

Morgan Stanley lifts the target

As Yahoo Finance reported on September 22, 2026, Morgan Stanley upgraded West Pharmaceutical Services to Overweight from Equalweight and raised its price target from USD 365 to USD 400.

The new target is USD 24.03 above the September 23 price, equivalent to 6.4 percent. That gap gives the upgrade a direct numerical link to the stock's latest valuation rather than relying only on the rating change.

Revenue beats the Q2 estimate

West Pharmaceutical Services delivered Q2 2026 revenue of USD 872.3 million, according to MarketBeat. Revenue was 13.8 percent higher than in the same quarter a year earlier and exceeded the USD 839.98 million consensus estimate.

The same Q2 report showed earnings per share of USD 2.37 against consensus of USD 2.08, a USD 0.29 beat. Fiscal 2026 EPS guidance was set at USD 8.85 to USD 9.05, while Q3 guidance stood at USD 2.14 to USD 2.24.

Stock stays near the yearly high

The September 23 market capitalization was USD 26.46 billion, while the 52-week range was USD 223.83 to USD 386. The price therefore sits 67.96 percent above the yearly low and within 2.6 percent of the yearly high.

For investors, the key tension is numerical: Q2 revenue growth and the earnings beat support the upgraded view, while the share price already trades close to its annual peak. The next test is whether the guidance range translates into another earnings beat.

NYSE price sets the reference

West Pharmaceutical Services stock was priced at USD 375.97 on the NYSE on September 23, 2026. The company operates in healthcare, specifically medical instruments and supplies, with products used in pharmaceutical packaging and drug delivery.